Commerce Bank Sells 102 Shares of Illumina, Inc. (ILMN)

Commerce Bank lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,527 shares of the life sciences company’s stock after selling 102 shares during the quarter. Commerce Bank’s holdings in Illumina were worth $265,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Principal Financial Group Inc. lifted its stake in shares of Illumina by 5.3% during the second quarter. Principal Financial Group Inc. now owns 235,074 shares of the life sciences company’s stock worth $40,790,000 after purchasing an additional 11,843 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Illumina by 1.4% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after purchasing an additional 43 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Illumina by 298.7% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock worth $1,813,000 after purchasing an additional 7,827 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in shares of Illumina by 35.7% during the second quarter. Neuberger Berman Group LLC now owns 4,893 shares of the life sciences company’s stock worth $849,000 after purchasing an additional 1,286 shares in the last quarter. Finally, Tobam lifted its stake in shares of Illumina by 5.2% during the second quarter. Tobam now owns 213,769 shares of the life sciences company’s stock worth $37,093,000 after purchasing an additional 10,557 shares in the last quarter. Institutional investors own 93.34% of the company’s stock.

Shares of Illumina, Inc. (NASDAQ ILMN) opened at 212.24 on Tuesday. The firm has a market cap of $30.99 billion, a P/E ratio of 42.58 and a beta of 0.81. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $212.40. The stock’s 50 day moving average price is $193.03 and its 200-day moving average price is $179.01.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. The company had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $0.86 earnings per share. Equities research analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Commerce Bank Sells 102 Shares of Illumina, Inc. (ILMN)” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/09/12/commerce-bank-sells-102-shares-of-illumina-inc-ilmn.html.

A number of brokerages have commented on ILMN. Vetr cut Illumina from a “buy” rating to a “hold” rating and set a $209.78 price objective on the stock. in a research note on Thursday, August 31st. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Barclays PLC reiterated an “equal weight” rating and issued a $150.00 price target on shares of Illumina in a research note on Wednesday, August 9th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and boosted their price target for the stock from $170.00 to $215.00 in a research note on Monday, August 7th. Finally, BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a research note on Monday, August 7th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. Illumina currently has a consensus rating of “Hold” and a consensus price target of $177.01.

In other news, Director Jay T. Flatley sold 22,540 shares of Illumina stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at $105,252,546.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $178.21, for a total transaction of $3,564,200.00. Following the transaction, the director now directly owns 534,176 shares in the company, valued at $95,195,504.96. The disclosure for this sale can be found here. Over the last three months, insiders have sold 165,705 shares of company stock worth $31,202,418. Insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply